for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Qiagen NV

QGEN.N

Latest Trade

35.66USD

Change

-0.10(-0.28%)

Volume

414,976

Today's Range

35.57

 - 

36.22

52 Week Range

25.06

 - 

43.16

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
35.76
Open
36.05
Volume
414,976
3M AVG Volume
60.01
Today's High
36.22
Today's Low
35.57
52 Week High
43.16
52 Week Low
25.06
Shares Out (MIL)
226.49
Market Cap (MIL)
8,254.46
Forward P/E
25.54
Dividend (Yield %)
--

Next Event

Q4 2019 Qiagen NV Earnings Release

Latest Developments

More

Qiagen Builds On Global Collaboration With Amgen For Companion Diagnostic Development In Non-Small Cell Lung Cancer

Qiagen Says Concludes Strategic Alternatives Review

Qiagen And Diasorin Receive FDA Approval For Liaison Quantiferon-TB Gold Plus Test

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Qiagen NV

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Industry

Biotechnology & Drugs

Contact Info

Hulsterweg 82

+31.77.3556600

https://www.qiagen.com/

Executive Leadership

Hakan Bjorklund

Independent Chairman of the Supervisory Board

Thierry Bernard

Interim Chief Executive Officer, Member of the Executive Committee

Roland Sackers

Managing Director, Chief Financial Officer, Member of the Executive Committee

Barthold Piening

Senior Vice President, Head of Global Operations, Member of the Executive Committee

Annette Koch

Senior Vice President and Chief Human Resources Officer, Member of the Executive Committee

Key Stats

2.86 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

1.3K

2017

1.4K

2018

1.5K

2019(E)

1.5K
EPS (USD)

2016

1.110

2017

1.270

2018

1.340

2019(E)

1.400
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.44
Price To Book (MRQ)
3.28
Price To Cash Flow (TTM)
40.66
Total Debt To Equity (MRQ)
71.40
LT Debt To Equity (MRQ)
68.44
Return on Investment (TTM)
-0.60
Return on Equity (TTM)
-0.49

Latest News

Latest News

German stocks - Factors to watch on January 14

The following are some of the factors that may move German stocks on Tuesday:

European markets ends festive week at fresh record highs

European stocks wrapped up a holiday-thinned week at record highs on Friday as growing hopes that a Sino-U.S. trade deal would be inked soon, as well as the latest dose of upbeat China data supported prospects of an improving global growth.

Festive European markets notch another record high

European shares rose to another record high on Friday, as investors remained optimistic about an improving global economy after a fresh dose of upbeat economic data from China and firming indications of a preliminary U.S.-China trade deal.

German stocks - Factors to watch on December 27

The following are some of the factors that may move German stocks on Friday:

Qiagen decides against sale following review, shares fall

Genetic testing firm Qiagen NV <QIA.DE> <QGEN.N> said on Tuesday it has concluded a review of potential alternatives, including a sale of the company, and determined that continuing to be a stand-alone business is its best option.

Qiagen decides against sale following review

Genetic testing firm Qiagen NV said on Tuesday it has concluded a review of potential alternatives, including a sale of the company, and determined that continuing to be a stand-alone business is its best option.

Siemens Healthineers says has no interest in buying Qiagen

German health technology company Siemens Healthineers is not interested in a takeover of Qiagen, the genetic testing company which last month said it would start talks with several potential suitors.

European stocks end flat as defensive gains offset auto slide

European stocks ended flat on Monday as a spurt of defensive buying over uncertainty surrounding U.S.-China trade talks helped temper losses in the auto sector.

CORRECTED-UPDATE 1-European stocks stall as auto tariff worries weigh

A bidding war for Spanish bourse BME and gains in defensive stocks propped up European markets on Monday, although doubts on whether or not the United States will impose tariffs on EU carmakers weighed on shares.

Qiagen shares surge as diagnostics group says open to takeover talks

Qiagen NV shares jumped to their highest in almost 19 years on Monday after the German genetic testing company said it would start talks with several potential suitors.

European shares extend winning streak; Qiagen jumps as company explores sale

European shares edged closer to a record level on Monday, as optimism around U.S.-China trade talks and a surprise move by China's central bank in cutting a key interest rate painted an upbeat picture about global growth.

German stocks - Factors to watch on November 18

The following are some of the factors that may move German stocks on Monday:

Qiagen exploring sale after indications of interest

Qiagen NV <QGEN.O> said on Friday it has started reviewing options, including sale, after the genetic testing company received several indications of interest for acquisition, sending its U.S. listed shares up 8.5%.

Qiagen exploring sale after indications of interest

Qiagen NV said on Friday it has started reviewing options after the healthcare company got several indications of interest for acquisition.

Deals of the day-Mergers and acquisitions

The following bids, mergers, acquisitions and disposals were reported by 2200 GMT on Thursday:

European shares hit by Daimler warning, weak economic data

European shares closed lower on Thursday as a warning from German carmaker Daimler and weak economic data from major economies added to concerns about a global slowdown.

Deals of the day-Mergers and acquisitions

The following bids, mergers, acquisitions and disposals were reported by 1100 GMT on Thursday:

European shares slip, Daimler drags on Germany

European shares dipped lower in early trade on Thursday, as a drop in Daimler shares and lackluster economic data from Asia as well as Europe, checked any gains from a handful of positive corporate updates.

German stocks - Factors to watch on November 14

The following are some of the factors that may move German stocks on Thursday:

Thermo Fisher approaches genetic testing specialist Qiagen for deal: Bbg

Instruments maker Thermo Fisher Scientific Inc <TMO.N> has approached genetic testing specialist Qiagen NV <QIA.DE> <QGEN.N> about a potential deal, Bloomberg https://www.bloomberg.com/news/articles/2019-11-13/thermo-fisher-said-to-weigh-purchase-of-diagnostics-firm-qiagen...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up